



/ immatics receives BMBF grant for development of product candidates for cancer immunotherapy of gastric carcinoma /

(Tuebingen, August 1st, 2005) – immatics, a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics, receives funding as part of the BioProfile grant programme from the Federal Ministry of Education and Research (BMBF) for development of novel product candidates for the treatment of gastric carcinoma (“GCa Project”). The volume of the project amounts to more than € 1.2 million with the BMBF grant amounting to more than €600,000.

The GCa Project will be conducted in cooperation with the Department of Immunology (Prof. Hans-Georg Rammensee) and the Department of Surgery (Prof. Alfred Königsrainer) from the University Hospital Tübingen, Germany.

About BioProfile

The funding programme from the Federal Ministry for Education and Research, "BioProfile" intends to support selected regions in Germany with a strong basis in the development of product-oriented applications of modern biotechnology. Since 2001, the “BioRegion Stuttgart / Neckar-Alb”, which includes the city of Tübingen, has been one of three regions in Germany receiving support from the BMBF through the BioProfile Programme.

About immatics

Founded in 2000, immatics biotechnologies GmbH is an independent biopharmaceutical company based in Tübingen, Germany. immatics uses proprietary technologies to identify and validate new products for treating various cancers. The products of immatics comprise short peptides stimulating the patient's own immune system to recognize and attack tumour cells. In addition to the clinical development of the product candidate IMA901 for the treatment of renal cell cancer, immatics also focuses on the characterization of relevant tumour associated peptides (“TUMAPs”) for the development of pharmaceutical products for immunotherapy of common cancers with high unmet medical need.